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Discussion
Dr Brian F. Buxton (Melbourne, Australia). This paper has some
fascinating aspects to it. One is the sequential rate of angiography
and the second is the excellent results obtained by off-pump surgery.
Let me just run through some of the aspects of this study. This is
a single-center, in fact almost a single-surgeon, retrospective obser-
vational study of 240 out of 402 patients who had off-pump surgery,
60% of whom had repeat angiography unrelated to symptoms. The
sequential angiograms were obtained the day after surgery and at 1
year and 5 years. I will confine most of my comments to the main
groups rather than the subset analyses presented toward the end.
First, the 5-year angiographic patency studies of the ITA grafts
were absolutely excellent, with 92% and 93% 5-year patency for
the OPCAB series. In particular, I noted that most or many of the
right ITA grafts were in situ. In contrast, the RGEA had 83% and
saphenous vein 74% 5-year patency results. There were insufficient
radial arteries in this small series to comment on the patency rates.
However, these results overall do confirm the excellent results in
the hands of the Korean surgeons in terms of their OPCAB series.
The second point is that the overall patency in relation to target
arteries provides no real new information. We know that the right
ITA patency is superior to the LCX and RCA, and that was con-
firmed by these studies.
I think of special interest in this paper are the data provided by
the progression of disease in the FitzGibbon 50% stenosis or Fitz-
Gibbon B group. This showed several interesting facts. In some of
the patients the lesions recovered and in other patients new type B
lesions appeared.
Let me run through the progression of disease. The ITA grafts
showed very little progression of disease. There were two time
frames, zero time to 1 year and 1 year through 5 years, and these fail-
ure rates were 4% and 6%, respectively. If we then look at the RGEA
grafts, similar figures were 10% for the first 1-year increment and
then 6% for the 4 years after that. In contrast, the saphenous vein
grafts had double the failure rate of the arterial grafts, even in that
relatively short follow-up period of 5 years.
We noted the same observations in our own series published by
Shah and associates, that is, that there is very little progression of
disease in arterial grafts but quite significant progress in arterial
grafts in a slightly longer follow-up period.
It does appear that saphenous vein graft patency may have im-
proved more recently with careful preparation, use of vasodilators,
adequate storage techniques, and secondary prevention of the pa-
tients after surgery. It may be that this improvement in graft patency,
if it is real, will require longer follow-up of these studies to obtain
sufficient late data.
Let me just run over some of the deficiencies of this excellent
paper. First, it is a single-surgeon, single-institution study, and
one raises the question about generalizability of these results. Are
we always as good as the Koreans?
Second, it is a retrospective study and therefore data quality
comes into question.
I think the most disappointing thing from my perspective is that
there was no comparison between off-pump and on-pump surgery.
There were no control data, which would be absolutely fascinating.
I suspect this could be done in the future prospectively in a way that
would give us some really meaningful answers to the question, is
off-pump surgery patency as good as on-pump? I think that is the
real question that most of us have in mind.
Fourth, there is not really good documentation of the native ves-
sel disease. In other words, how many vessels had serious compet-
itive flow at low-grade stenoses?
I have four questions: What technique did you use to implant the
right ITA? Did you go across the anterior midline or through the
transverse sinus as a Y graft from the left?
Dr Kim. In this series, the right ITA was used to revascularize
the LAD territory by crossing the midline, the ramus, or high obtuse
marginal branch through the transverse sinus, and sometimes the
RCA or posterior descending artery as an in situ graft. If the right
ITA was too short to reach the left coronary territory or if the left cor-
onary territory could not be completely revascularized with bilateral
in situ ITA grafts, a Y graft was constructed.
Dr Buxton. Second question: Most surgeons prefer or perhaps
are more familiar with the Kaplan–Meier estimation of graft
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patency, and this can be done at zero time, 1, and 5 years. Why did
you choose to use elective time estimates of 1 and 5 years?
Dr Kim. We studied 240 patients who received all the early, 1-
year, and 5-year follow-up angiograms. For the analysis of the serial
changes over the 5-year period, we used nonparametric c2 test with
McNemar examination. We did not use the Kaplan–Meier estima-
tion because we could not recognize the exact time of graft occlu-
sions.
Dr Buxton. Perhaps there are not so many assumptions made in
your results as ours that might derive from a Kaplan–Meier analysis.
One of the difficult things about looking at graft angiograms, and
particularly anastomotic lesions and stenoses, is the validity and re-
producibility of the observations. Can you tell us how many people
looked and how independent the observers were in assessing the
level of graft stenoses?
Dr Kim. Our cardiologists performed the angiograms and put
their initial interpretations. For this study, one physician initially re-
viewed all the angiograms and consensus was reached after review.
Dr Buxton. One last question: Forty percent of the patients had
missing data. Is there any reason for that? Did their grafts all fail?
What happened? Why were they missing?
Dr Kim. As I mentioned before, patients who missed any of the
three postoperative serial angiograms were excluded from this
study. In this study, 240 patients who received all three follow-up
angiograms—early, 1 year, and 5 years—evaluation of the anasto-
motic sites and patency of the grafts, were studied.
Dr Volkmar Falk (Leipzig, Germany). I enjoyed your paper,
and I have one question. Would it be of value to go back and assess
the extent of coronary artery disease by applying the SYNTAX
score, which was designed to measure the extent of coronary artery
disease? You are in a unique position in that you have angiograms at
the time of surgery and 5 years after. You could finally tell us
whether the extent of coronary artery disease at the time of surgery
is really a predictor of late graft failure. That is one question that is
still kind of open and no one is really addressing this. Would you
consider doing that? I think this would be a great adjunct to your
current study.
Dr Damiano. Can you clarify what you mean by SYNTAX
score?
Dr Falk. I’m sorry; I thought that was common knowledge al-
ready. The SYNTAX trial was designed to compare treatment of tri-
ple vessel disease either by stenting or CABG. It was just finished,
so the enrollment is just finished. Specifically for this trial, a new
scoring system was developed to determine the extent of coronary
artery disease, because most of the trials do not really look at this.
Let’s say they enroll patients with triple vessel disease, but we all
know that there are various types of triple vessel disease that may
alter the outcome more so than any of the other risk factors that
are commonly applied, such as diabetes or hypertension. The extent
of coronary artery disease can be graded. There is a good score for
this that was actually designed for the SYNTAX trial but is avail-
able. It should be great to look at your angiograms again, apply
the score, and then after a period of time assess whether the extent
of coronary artery disease plays a role for late graft occlusion.
Dr Damiano. It is a good idea, but I think he will probably
have to go back and get the score and then report the data at a later
meeting.
Dr Kim. I would like to make some comments. As Dr Buxton
indicated, there are limitations to the present study. It was a retro-
spective study of a single surgeon in a single institution. It was
not performed in a randomized manner with regard to the type of
conduit and the target vessels. The majority of ITA grafts were
used to revascularize the left coronary territory and the majority of
RGEA grafts were used to revascularize the RCA territory. This
might serve as confounding variables. We have two staff surgeons
in the adult cardiac division of our institution. I do most of the iso-
lated CABGs with off-pump technique and the other surgeon does
most of the valvular and aortic operations. That is why this study
was a single-surgeon experience from a single institution. As we
performed OPCAB in most of patients during the study period, it
was difficult to obtain an on-pump control group to see the differ-
ence between off-pump and on-pump CABG.
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